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Background-—Control of blood pressure (BP) remains a major challenge in primary care. Innovative interventions to improve BP
control are therefore needed. By updating and combining data from 2 previous systematic reviews, we assess the effect of
pharmacist interventions on BP and identify potential determinants of heterogeneity.
Methods and Results-—Randomized controlled trials (RCTs) assessing the effect of pharmacist interventions on BP among
outpatients with or without diabetes were identiﬁed from MEDLINE, EMBASE, CINAHL, and CENTRAL databases. Weighted mean
differences in BP were estimated using random effect models. Prediction intervals (PI) were computed to better express
uncertainties in the effect estimates. Thirty-nine RCTs were included with 14 224 patients. Pharmacist interventions mainly
included patient education, feedback to physician, and medication management. Compared with usual care, pharmacist
interventions showed greater reduction in systolic BP (7.6 mm Hg, 95% CI: 9.0 to 6.3; I2=67%) and diastolic BP
(3.9 mm Hg, 95% CI: 5.1 to 2.8; I2=83%). The 95% PI ranged from 13.9 to 1.4 mm Hg for systolic BP and from 9.9 to
+2.0 mm Hg for diastolic BP. The effect tended to be larger if the intervention was led by the pharmacist and was done at least
monthly.
Conclusions-—Pharmacist interventions – alone or in collaboration with other healthcare professionals – improved BP
management. Nevertheless, pharmacist interventions had differential effects on BP, from very large to modest or no effect; and
determinants of heterogeneity could not be identiﬁed. Determining the most efﬁcient, cost-effective, and least time-consuming
intervention should be addressed with further research. ( J Am Heart Assoc. 2014;3:e000718 doi: 10.1161/JAHA.113.000718)
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E levated blood pressure (BP) is a major cause of deathworldwide.1 Although reduction of BP is a cornerstone of
the prevention of cardiovascular diseases (CVD),2 numerous
hypertensive patients do not achieve adequate BP control. In
the United States in 2009-2010, it was estimated that 53% of
all hypertensive people and 40% of treated hypertensive
people had uncontrolled BP.3 Lower rates of BP control have
been reported in European countries.4
Innovative interventions to improve BP control are there-
fore needed in primary care, where management of hyper-
tension takes place. One such approach is a greater use of
community-based models of care with the involvement of non-
physician healthcare professionals, speciﬁcally, pharmacists
and nurses.5,6 The US Community Preventive Services Task
Force has recently recommended team-based care, including
pharmacists, to improve BP control.7 Pharmacists are highly
accessible healthcare professionals and a valuable asset in
the management of hypertension.8,9 Recently, we conducted
a systematic review and meta-analysis of 30 RCTs underlining
that pharmacist interventions – conducted alone or in
collaboration with physicians or nurses – substantially
reduced systolic and diastolic BP and helped control other
major CVD risk factors (total and LDL cholesterol, smoking)
among outpatients with CVD risk factors.9 In a second
systematic review and meta-analysis of 15 RCTs, we showed
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that pharmacist interventions were associated with a better
control of systolic and diastolic BP and other major CVD risk
factors (total and LDL cholesterol, body mass index) among
outpatients with diabetes.10
However, in both systematic reviews, a major issue was
that various pharmacist interventions were evaluated in
different clinical settings with a substantial heterogeneity in
the effect estimates on BP. Therefore, some interventions are
possibly more efﬁcient than others to reduce BP. The
identiﬁcation of the more efﬁcient pharmacist interventions
on BP is of major importance to guide policy and to decide
which intervention should be recommended. However, it
requires the comparison of data on a large number of studies.
Therefore, we combined and updated BP data from these 2
previous systematic reviews to assess the effect of pharma-
cist interventions on BP among outpatients and to identify
determinants of heterogeneity.
Methods
Data were updated and combined from 2 previous systematic
reviews of RCTs in which we assessed the effect of
pharmacist interventions on CVD risk factors among
outpatients.9,10 Both reviews were conducted following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) recommendations11 and using meth-
ods outlined in the Cochrane Handbook for Systematic
Reviews of Interventions,12 including the preparation of a
protocol and analysis plan.
Research Methods
Details of the research methods are given in the original
publications.9,10 Brieﬂy, both reviews used the same selection
criteria (study design, interventions, and outcomes), search
strategy, study selection, data extraction, and assessment of
risk of bias across the included studies. The ﬁrst review
included patients with any modiﬁable CVD risk factors but
excluded studies, which targeted patients with diabetes.9 The
second review included only studies including patients with
diabetes.10 For both reviews, we included RCTs evaluating the
effect of pharmacist intervention delivered by a pharmacist
alone or in collaboration with other healthcare professionals,
among adult outpatients with any modiﬁable CVD risk factors
(hypertension, dyslipidemia, diabetes, smoking, or obesity)
compared with the usual care group.
Pharmacist interventions were classiﬁed using the a priori-
deﬁned categories of pharmacist-directed care (pharmacist
initiated and managed interventions) or as pharmacist
collaborative care (pharmacist collaborated in interventions
conducted with other health care professionals).13
Search strategy and study selection
The description of the search strategy and the ﬂow diagram of
assessed and included studies in each review are given in
detail in the 2 original publications.9,10 Brieﬂy, we searched, in
collaboration with a research librarian (A.L.C.), the following
electronic databases: MEDLINE via PubMed, EMBASE, CI-
NAHL, and CENTRAL for published articles using predeﬁned
search terms. The ﬁrst review, which excluded studies on
patients with diabetes, retrieved articles up to November
2010, while the second review of patients with diabetes
retrieved articles up to March 2012. For the current review, an
update of the original literature searches of both reviews was
conducted in September 2013. For the current review, we
considered only studies where systolic or diastolic BP was the
outcome and presented as weighted mean differences in BP.
Data extraction and assessment of risk of bias
A data extraction form was created and pilot tested with some
eligible studies and then ﬁnalized.
In both reviews, data extraction was independently pre-
formed by 2 authors (V.S. and A.C.). Discrepancies were
resolved through discussion. Extracted data included: (1) study
author, year of publication, and country where the study was
conducted; (2) study characteristics (including study setting
and design, duration of follow-up, and sample size);
(3) participants characteristics (including sex, age, CVD risk
factors, and medications); (4) characteristics of interventions
(including description and frequency of the pharmacist inter-
vention); (5) characteristics of usual care group; and (6) types of
outcome measure. Details of pharmacist interventions were
documented using the a priori-deﬁned categories of pharma-
cist-directed care or pharmacist collaborative care.13
The risk of bias for all included studies was independently
assessed by 2 authors (V.S. and A.C.) using the Cochrane Risk
of Bias Tool, a validated tool for quality in RCTs,12 which
addresses random sequence generation, allocation conceal-
ment, blinding of outcome assessors, completeness of
outcome data, selective outcome reporting, and other
potential bias (e.g., important baseline imbalance in patient
characteristics). Each of these 6 domains in the tool was rated
as (1) low risk of bias; (2) unclear risk of bias; and (3) high risk
of bias. A study was of high quality if it had a low risk of bias
on ≥4 of the 6 domains in the tool.
Statistical Analysis
Data were analyzed using Stata 12.0 software (StataCorp LP).
Outcomes of interest were systolic BP and diastolic BP.
Heterogeneity in the effect of interventions was expected
across studies and random effect models were used to
estimate intervention effects and 95% conﬁdence intervals
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(CI).14 Effects were calculated as weighted mean differences
in BP between intervention and usual care group.
Between studies heterogeneity was quantiﬁed using the I2
statistic. To better express uncertainties in the effect
estimates, 95% prediction intervals (PI) were computed
because they are advocated in case of substantial heteroge-
neity. While the CI quantiﬁes the accuracy of the mean effect,
the PI quantiﬁes the dispersion (or distribution) of effect
estimates15,16 and will include the true effect from a unique
study 95% of the time.16 The PI is wider than the CI unless
there is no heterogeneity.
Reasons for heterogeneity in effect estimates should be
sought in meta-analyses.14 To explore the possible sources of
heterogeneity, we conducted subgroup analyses according to
selected study characteristics: (1) country where the study
was conducted; (2) setting (outpatient clinic versus commu-
nity pharmacy); (3) including patients with diabetes or not;
(4) type of pharmacist care (pharmacist-led care versus
collaborative care); (5) type of interventions, (6) including a
nurse or not in the intervention; and (7) frequency of
intervention. Statistical signiﬁcance of between subgroup
differences was evaluated by meta-regression.17
Publication bias was evaluated with funnel plots to check
symmetrical distribution and convergence toward the pooled
effect, along with Egger tests. Further, sensitivity analyses
were performed (1) excluding relatively small studies (with
fewer than 80 participants per randomization group) and
(2) restricting analyses to studies of high quality.
Results
Study Selection
Initially, 30 RCTs with 19 studies having BP outcome were
included in the ﬁrst systematic review.9 Of the 5522
additional citations identiﬁed in the updated searches of this
ﬁrst review, 33 potentially relevant full-text studies were
assessed and screened; 10 additional RCTs met the inclusion
criteria, with 6 studies having BP as outcome. Initially, 15
RCTs with 12 studies having BP as outcome were included in
the second systematic review.10 Of the 2742 additional
citations identiﬁed in the updated searches of the second
review, 10 potentially relevant full-text studies were assessed
and screened; 2 additional RCTs met the inclusion criteria
with 2 studies having BP as outcome. Overall, with the update,
data from 39 RCTs with BP as outcome are included in the
current review.
Study and Patient Characteristics
Thirty-nine RCTs representing a total of 14 224 patients were
included for the current review. Trials were published between
1973 and 2013 in peer-reviewed journals. Details of included
studies are given in Table S1. Most trials were conducted in
the USA or Canada (N=25); 4 trials18–21 were conducted in
European countries and 10 trials22–31 in Asia, South America,
and Australia.
The within-study mean age of participants ranged from 48
to 77 years (mean, 62 years). Overall, 53% of participants
were women. The mean duration of follow-up was 8.3 months
(median, 6 months; range, 3 to 13 months). For most
trials19,20,22–28,30–52 (N=31), participants were followed-up in
outpatient clinics or by general practitioners; 6 trials8,18,19,53–55
were conducted in community pharmacy and 2 trials21,29 in
both outpatient clinics and community pharmacies.
The interventions were led by the pharmacist in 23 studies
and conducted in collaboration with other healthcare profes-
sionals, such as physician, nurse, dietitian, or physical
therapist, in 16 studies (Table S1). In the 16 pharmacist
collaborative care studies, the team composition was phar-
macist/physician (N=10); pharmacist/nurse/physician (N=3);
pharmacist/nurse/physician/dietitian or nutritionist thera-
pist (N=2), or pharmacist/nurse (N=1). Overall, a nurse was
involved in the intervention in 6 studies.
The interventions consisted of (1) patient education and
counseling about lifestyle, medication and medication adher-
ence (N=35 studies); (2) feedback to healthcare professional
(including drug-related problems identiﬁcation; recommenda-
tion to physician for medication change; team meeting,
development of treatment plan) (N=35); (3) medication
management (including drug monitoring with adjustment or
change in medication) (N=34); (4) measurement of BP,
hypertension staging and risk of stratiﬁcation, and reviewing
of home BP measurements (N=13); (5) reminder system
(including telephone contact, web services, home visits, or
drug adherence aid) (N=12); and (6) healthcare professional
education (including training program) (N=2).
The frequency of intervention was monthly or more
frequently in 17 studies and less frequently than once a
month in 11 studies. In the 11 remaining studies, the
frequency of intervention was irregular (e.g., at every patient
encounter) or not clearly speciﬁed.
Overall, study quality was moderate (Figure S1), with
considerable variation in quality. Sixteen studies were
considered of relatively high quality. In all studies, the
participants were not blinded to the intervention.
Main Results
The outcome included systolic BP in 39 studies, involving
14 224 patients, and diastolic BP in 36 studies, involving
13 826 patients. On average, pharmacist interventions were
associated with a large reduction in systolic and diastolic BP
of 7.6 mm Hg (95% CI: 9.0 to 6.3 mm Hg) and
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3.9 mm Hg (95% CI: 5.1 to 2.8 mm Hg), respectively
(Figures 1A and 1B). There was a substantial heterogeneity
for systolic (I2=67%) and diastolic BP (I2=83%). The 95% PI
ranged from 13.9 to 1.4 mm Hg for systolic BP and from
9.9 to +2.0 mm Hg for diastolic BP.
Subgroup Analyses
Results of subgroup analyses according to selected study
characteristics are summarized in Table. No difference was
observed in BP reductions according to the country where the
study was conducted, to the type of interventions (data not
shown), to the involvement or not of a nurse in the
intervention, or to the inclusion or not of patients with
diabetes. The effect was slightly better if the intervention was
conducted in community pharmacies. A more substantial
difference in effect on BP was observed according to the type
of pharmacist care, pharmacist-led care being associated with
a larger effect on systolic and diastolic BP compared with
collaborative care (Table, Figures 2A and 2B; systolic BP:
8.5 mm Hg [95% CI, 10.0 to 7.0 mm Hg] versus
6.3 mm Hg [95% CI, 8.0 to 4.5], P=0.046; diastolic
BP: 4.6 mm Hg [95% CI, 5.7 to 3.4 mm Hg] versus
2.8 mm Hg [95% CI, 4.4 to 1.2 mm Hg], P=0.10).
Furthermore, the effect on BP tended to be more important
if the intervention was conducted monthly or more frequently
compared with less frequently than once a month (Table,
Figures 3A and 3B; systolic BP: 9.1 mm Hg [95% CI, 11.4
to 6.7 mm Hg] versus 6.7 mm Hg [95% CI, 9.1 to
4.4 mm Hg], P=0.14; diastolic BP: 4.5 mm Hg [95% CI,
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Figure 1. Forest plot of the mean difference in (A) systolic and (B) diastolic blood pressure with
pharmacist care compared with usual care group. n=number of participants.
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6.1 to 2.9] versus 1.9 mm Hg [95% CI, 3.5 to
0.3 mm Hg], P=0.08). Nevertheless, the differences
between these subgroups reached statistical signiﬁcance
(P<0.05) only for the difference in systolic BP according to the
type of pharmacist care. Furthermore, the between-study
heterogeneity within subgroups remained substantial in most
analyses.
Publication Bias and Sensitivity Analysis
Asymmetries in the funnel plots were observed for both
systolic and diastolic BP. The Egger test results were
statistically signiﬁcant (P<0.001 for systolic BP; P<0.001 for
diastolic BP). To account for this potential publications bias
and to evaluate the impact of relatively small studies, we
conducted a ﬁrst sensitivity analysis restricted to the 19
studies with >80 patients per arm. For these studies, the
weighted mean difference between pharmacist intervention
and usual care was 7.0 mm Hg (95% CI, 8.7 to
5.4 mm Hg; I2=72%) for systolic BP and 3.1 mm Hg
(95% CI, 4.4 to 1.8 mm Hg; I2=84%) for diastolic BP.
These differences were of the same magnitude compared with
the differences observed when all studies were included.
The second sensitivity analysis was restricted to the 16
studies of relatively high quality. For these studies, the
weighted mean difference between pharmacist intervention
and usual care was 7.3 mm Hg (95% CI, 8.6 to
6.0 mm Hg; I2=8%) for systolic BP and 3.6 mm Hg (95%
CI, 4.6 to 2.6 mm Hg; I2=41%) for diastolic BP. These
differences were of the same magnitude compared with the
differences observed when all studies were included.
Discussion
By updating and combining data from our previous systematic
reviews, we analyzed data from 39 RCTs including 14 224
outpatients. Findings from the current review are similar to
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Figure 1. Continued.
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those of the 2 previous systematic reviews: positive evidence
was found supporting pharmacist interventions for improving
systolic and diastolic BP control among outpatients. The
observed effect was indeed substantial compared with
powerful antihypertensive drugs like loop diuretics that
decrease systolic blood pressure, on average, by 8 mm Hg.56
The interventions – conducted by the pharmacist alone or in
collaboration with physician, nurse or dietitian, or physical
therapist – were most often educational interventions to
patients about medication, lifestyle and physical activity,
feedback to physician (such as recommendation regarding
medications changes or problems to medication adherence),
and medication management (such as drug monitoring with
adjustment or change in medication). A substantial heteroge-
neity in the effect estimate was observed for both systolic and
diastolic BP. Although our subgroup analyses could not
explain this heterogeneity, interventions led by the pharmacist
tended to be more effective. Furthermore, interventions
conducted at least monthly might be more effective,
albeit the difference did not reach statistical signiﬁcance.
Finally, wide prediction intervals were observed, suggesting
differential effects of pharmacist interventions on BP in
individual studies, from a very large effect to modest or no
effect.
Findings from the current systematic review and meta-
analysis are consistent with previous reviews showing that
pharmacist-led care or involved in a team-based care with
physician or nurse improves patient health outcomes6,57
including BP control.5,9,10 In most RCTs included in this
updated and combined review, complex pharmacist interven-
tions with multiple components (i.e., co-interventions) were
evaluated, making it difﬁcult to identify precisely which
component of the intervention was more potent to control BP.
Despite the large number of included studies, our analyses did
not clearly identify which (aspect of the) intervention is the
most efﬁcient. We have shown in a previous review that the
number of interventions was not associated with a better BP
control.9 In this current combined review, we observed a
slightly larger effect on BP with pharmacist-led care compared
with pharmacist interventions implemented in collaboration
Table. Subgroup Analyses for the Difference in Systolic and Diastolic Blood Pressure With Pharmacist Care Compared With Usual
Care Group According to Study Characteristics
Study Characteristics
Systolic Blood Pressure Mean
Difference (mm Hg)
Between Subgroup
Differences
Diastolic Blood Pressure Mean
Difference (mm Hg) Between Subgroup Difference
N (95% CI) P Value N (95% CI) P Value
Country
US/Canada 25 7.8 (9.6 to 6.1) Ref 22 4.1 (5.5 to 2.7) Ref
Other countries 14 7.3 (9.2 to 5.4) 0.83 14 3.7 (5.3 to 2.2) 0.76
Setting
Outpatient clinics/GP 31 7.5 (8.9 to 6.1) Ref 29 4.0 (5.2 to 2.7) Ref
Community pharmacy 6 10.5 (15.7 to 5.3) 0.29 5 5.0 (7.6 to 2.3) 0.51
Other 2 4.9 (9.0 to 0.7) 0.39 2 0.7 (2.5 to 2.7) 0.22
Targeted patients
Without diabetes 25 8.2 (10.0 to 6.3) Ref 25 3.7 (5.0 to 2.5) Ref
With diabetes 14 6.4 (7.8 to 5.1) 0.37 11 4.5 (6.3 to 2.8) 0.51
Pharmacist care
Collaborative care 16 6.3 (8.0 to 4.5) Ref 14 2.8 (4.4 to 1.2) Ref
Pharmacist-led care 23 8.5 (10.0 to 7.0) 0.046 22 4.6 (5.7 to 3.4) 0.10
Nurse interventions
Without nurse 33 7.8 (9.3 to 6.3) Ref 32 4.0 (5.1 to 2.8) Ref
With nurse 6 6.5 (8.5 to 4.4) 0.65 4 3.8 (7.7 to 0.1) 0.92
Frequency of intervention
Once a month or more frequently 17 9.1 (11.4 to 6.7) Ref 16 4.5 (6.1 to 2.9) Ref
Less than once a month 11 6.7 (9.1 to 4.4) 0.14 9 1.9 (3.5 to 0.3) 0.08
Irregular or not clearly specified 11 7.1 (8.6 to 5.6) 0.22 11 4.6 (6.1 to 3.0) 0.93
N indicates number of studies.
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with other health professionals. Nevertheless, the difference
was modest.
Our ﬁndings that the effect on BP was slightly greater if the
intervention was led by the pharmacist differ to some extend
from a recent umbrella review of systematic reviews evalu-
ating the effectiveness of community pharmacist interven-
tion.58 Mossialos et al58 reported mixed or inconclusive
evidence in support of expanding the role of community
pharmacist in healthcare delivery. One reason for the
difference may be that the review by Mossialos et al58 was
focused speciﬁcally on community pharmacists. Our review
evaluated not only studies with community pharmacist
interventions but also clinical pharmacist interventions work-
ing, for example in outpatient clinic or medical groups.
Nevertheless, we agree with Mossialos et al58 that expanding
the role of community pharmacist needs signiﬁcant changes
in healthcare systems, further training of pharmacists and
involves policy development.
Furthermore, based on a thorough review, the team-based
hypertension care has been recently recommended by
the US Preventive Services Task Forces as an effective
strategy to improve BP, with nonphysician healthcare
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Figure 2. Forest plot of the mean difference in (A) systolic and (B) diastolic blood pressure with
pharmacist care compared with usual care group according to type of care (pharmacist-led care vs
collaborative care). n=number of participants.
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professionals – involving pharmacist, nurses, dietitian – working
in collaboration with physician and sharing responsibilities of
hypertension care.7 Comparative effectiveness studies are
therefore needed to determine the most efﬁcient interventions
and long-term effect.
Potentially important components of effective pharmacist
interventions such as adequate pharmacist training (e.g.,
measurement of BP or management of hypertension) and
remuneration for services (e.g., reviews of medications,
resolution of drug related-problems, patient counseling to
improve adherence) should be considered to better under-
stand the heterogeneity of the results of pharmacist inter-
ventions reported here. Another possible factor that might
explain the reported difference in the reviewed papers is the
various types of healthcare delivery system. Indeed, pharma-
cist involvement is typical and well accepted in the care, for
example in the United States or in Canada, compared with
European countries, and that could inﬂuence the effect size of
pharmacist interventions. Obstacles to the implementation
of intervention should be also considered. It would be
especially relevant for policy recommendations to have such
information. However, and this is one limitation of the current
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Figure 2. Contiuned.
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review, information about these factors was not available or
only partly reported in the studies identiﬁed.
To better express uncertainties in the effect estimates of
pharmacist intervention, we reported prediction intervals.15,16
When there is substantial heterogeneity, the interpretation of
the mean effect and the related conﬁdence interval may be
problematic, especially when the statistical heterogeneity is
due to true clinical heterogeneity.15 Prediction interval reveals
the distribution of effect estimates for individual studies, and
our results suggest that there could be large differences in
effect estimates, with some intervention having modest or no
effect on BP. Prediction interval gives the range of effects that
would be expected from a new study with similar character-
istics to the current studies. Reporting prediction intervals can
be enlightening especially when complex healthcare interven-
tions, with expected true clinical heterogeneity in their
effects, are evaluated.
Some limitations should be considered in interpreting the
results of this study. Asymmetries in funnel plots were clearly
observed for systolic and diastolic BP, and this may reﬂect a
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Figure 3. Forest plot of the mean difference in (A) systolic and (B) diastolic blood pressure with
pharmacist care compared with usual care group according to frequency of intervention (once a month or
more frequently, less than once a month, irregularly/not speciﬁed). n=number of participants.
DOI: 10.1161/JAHA.113.000718 Journal of the American Heart Association 9
Meta-analysis of Pharmacist Care in Hypertension Santschi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
publication bias.59 Indeed, such a bias is possible because we
did not search systematically for unpublished studies and
because small studies showing no or weak effect of pharmacist
intervention may not have been published. Nevertheless, our
sensitivity analyses did not suggest any major impact of small
studies on the effect estimates. Furthermore, the asymmetry
may also be due to other factors, such as the heterogeneity of
the effect of interventions.59 The difference reached statistical
signiﬁcance only for the difference in the effect on systolic BP
between collaborative care and pharmacist-led care. However,
statistical tests with meta-regression in meta-analyses are
known to have low power to show statistically signiﬁcant
differences between subgroups. The absence of statistically
signiﬁcant differences does not exclude the possibility of a true
and clinically relevant difference in effect size. Therefore, we
considered with precaution that the effect size could differ
according to the frequency of interventions and the type of care
despite the absence of statistically signiﬁcant differences in
most comparisons.
Another limitation is that the quality of studies was
moderate on average. A reassuring observation is the
consistency of the effect on BP when the analysis was
restricted to high-quality studies: no difference was observed
compared to the effect estimates when all studies were
included. The relatively short duration of follow-up (median of
6 months) is also a limitation. It is indeed possible that the
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Figure 3. Contiuned.
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effect of pharmacist interventions could be reduced over a
longer duration of follow-up, as reported in a recent RCT
evaluating the effect of home BP telemonitoring and pharma-
cist management on BP control.43 Finally, a cost-effectiveness
analysis of these interventions is lacking. This would help
determine which intervention should be preferably
implemented.
In addition to contributing to the current state of literature
supporting the beneﬁcial effects of pharmacists interventions
in BP control, our ﬁndings underline that the impact of long-
term (e.g., >1 year) pharmacist interventions on BP control is
lacking. Moreover, most of the included studies evaluating the
impact of pharmacist care on BP among outpatients were
conducted in the United States and Canada, reﬂecting an
enhanced and more successfully implemented role of phar-
macist in these healthcare systems.
Conclusions
Our meta-analysis shows evidence that pharmacist interven-
tions improve BP control in outpatients compared with usual
care. Given the large heterogeneity between studies, it is
difﬁcult to predict which effect size would be expected when
implementing such interventions in practice. Comparative
effectiveness studies, with a long duration of follow-up, are
still needed to determine the most efﬁcient, implementable,
cost-effective, and least time-consuming intervention for
improving BP control in various healthcare systems.
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